Regulation of infectious spore formation in the fungal pathogen Coccidioides posadasii
- Institution
- UNIVERSITY OF CALIFORNIA BERKELEY, CA
- Principal investigator
- Rachel Beth Brem
- Funding
- $438K
- Duration
- 2025–2027
Moonbase score
Still being scored
Abstract
SUMMARY The human fungal pathogen Coccidioides causes Valley Fever, a treatment-refractory and sometimes deadly disease prevalent in arid regions of the western hemisphere. Patients contract the disease by inhaling fungal spores from soil. Understanding Coccidioides behavior in the environment is thus key to public health measures for Valley Fever prediction and prevention. We propose a first-ever molecular study of the environmental life cycle of Coccidioides toward this end. Our preliminary work has shown that Coccidioides preferentially makes infectious spores in dry conditions. We now want to know how. We apply experimental- and computational- genomic approaches to dissect desiccation response in Coccidioides outside the host. The rich data sources we generate will pinpoint candidate genes underlying spore formation and will also position us to discover other environmentally-triggered phenotypes in Coccidioides. Our work will open a new wing of the research literature focused on the molecular basis of Coccidioides disease transmission from the environment.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF CALIFORNIA BERKELEY
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of California BerkeleyNot yet scored
Mapping deep evolutionary divergences in cellular models of stress response
Rachel Beth Brem · $460K · 2017–2027
- NIH · University of California Berkeley48
Leveraging Single Cell Stimulation to Untangle Parallel Perceptual Pathways in the Human Retina
Leah Johnston · $47K · 2024–2027
- NIH · University of California Berkeley48
Discovery and Development of Organic Reactions Catalyzed by Transition Metals Valuable for Medicinal Chemistry
John F Hartwig · $832K · 2019–2027